Pfizer, Mylan Push To Pare Down EpiPen Class Action

By Kevin Stawicki · July 16, 2020, 8:26 PM EDT

EpiPen manufacturer Pfizer and distributor Mylan asked a Kansas federal judge to pare down remaining claims in multidistrict litigation over the price of the emergency allergy treatment, saying EpiPen buyers failed...

To view the full article, register now.

Try a seven day FREE Trial

Already a subscriber? Click here to login

Documents

Case Information

Case Title

In Re: Epipen (Epinephrine Injection, USP) Marketing, Sales Practices and Antitrust Litigation

Case Number

Court

Kansas

Nature of Suit

Personal Inj. Prod. Liability

Date Filed

August 04, 2017

Recent Articles By Kevin

May 19, 2021
Labor Unions Say CDC Mask Advice Ignores Science, Equity
May 14, 2021
Med Clinic's Walkout Firings Were Illegal, NLRB Judge Says
May 06, 2021
NLRB Health Unit Closure Broke CBA, Labor Panel Says
May 03, 2021
Split NLRB Says GWU Hospital Didn't Illegally Brush Off Union
April 20, 2021
Nursing Home Slams Union's 'Illegitimate' Bid To Block Sale
April 14, 2021
SEIU Unit Sues To Block Nursing Home's Imminent Sale
March 19, 2021
NLRB Says Union's Misconduct Can't Undo Election Win
March 15, 2021
FDNY Workers Can't Proceed As Class In Bias Suit, NYC Says
February 17, 2021
Union's 'Opprobrious' Conduct Voids Election Vote, Biz Says
December 16, 2020
NLRB Official Says Pooled CBA Vote Can't Block Union Ouster